ElNahid M, Issac M, Marzouk Sadek K
Sci Rep. 2023; 13(1):19002.
PMID: 37923735
PMC: 10624883.
DOI: 10.1038/s41598-023-45750-8.
Hong S, Wang H, Zhang Z, Qiao L
Steroids. 2022; 183:109022.
PMID: 35346661
PMC: 8956351.
DOI: 10.1016/j.steroids.2022.109022.
Devresse A, De Greef J, Yombi J, Belkhir L, Goffin E, Kanaan N
Transplant Direct. 2022; 8(3):e1292.
PMID: 35187216
PMC: 8843373.
DOI: 10.1097/TXD.0000000000001292.
Moosazadeh M, Mousavi T
J Med Virol. 2021; 94(4):1350-1356.
PMID: 34850411
PMC: 9015319.
DOI: 10.1002/jmv.27489.
Rubio-Rivas M, Forero C, Mora-Lujan J, Montero A, Formiga F, Homs N
Pharmacotherapy. 2021; 41(11):884-906.
PMID: 34558742
PMC: 8661749.
DOI: 10.1002/phar.2627.
Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study.
Russo G, Solimini A, Zuccala P, Zingaropoli M, Carraro A, Pasculli P
PLoS One. 2021; 16(9):e0257376.
PMID: 34506608
PMC: 8432821.
DOI: 10.1371/journal.pone.0257376.
Combination therapy of Tocilizumab and steroid for management of COVID-19 associated cytokine release syndrome: A single center experience from Pune, Western India.
Dravid A, Kashiva R, Khan Z, Memon D, Kodre A, Potdar P
Medicine (Baltimore). 2021; 100(29):e26705.
PMID: 34398044
PMC: 8294888.
DOI: 10.1097/MD.0000000000026705.
The signal pathways and treatment of cytokine storm in COVID-19.
Yang L, Xie X, Tu Z, Fu J, Xu D, Zhou Y
Signal Transduct Target Ther. 2021; 6(1):255.
PMID: 34234112
PMC: 8261820.
DOI: 10.1038/s41392-021-00679-0.
A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms.
Langarizadeh M, Tavakoli M, Abiri A, Ghasempour A, Rezaei M, Ameri A
EXCLI J. 2021; 20:339-365.
PMID: 33746666
PMC: 7975631.
DOI: 10.17179/excli2020-3196.
[Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation].
Aomar-Millan I, Salvatierra J, Torres-Parejo U, Nunez-Nunez M, Hernandez-Quero J, Anguita-Santos F
Med Clin (Barc). 2021; 156(12):602-605.
PMID: 33622529
PMC: 7843156.
DOI: 10.1016/j.medcli.2021.01.006.
Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider.
Alunno A, Najm A, Mariette X, De Marco G, Emmel J, Mason L
Ann Rheum Dis. 2021; 80(6):803-815.
PMID: 33589438
PMC: 8142448.
DOI: 10.1136/annrheumdis-2020-219725.
Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review.
Lariccia V, Magi S, Serfilippi T, Toujani M, Gratteri S, Amoroso S
J Clin Med. 2020; 9(12).
PMID: 33322733
PMC: 7763517.
DOI: 10.3390/jcm9124021.
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.
Stone J, Frigault M, Serling-Boyd N, Fernandes A, Harvey L, Foulkes A
N Engl J Med. 2020; 383(24):2333-2344.
PMID: 33085857
PMC: 7646626.
DOI: 10.1056/NEJMoa2028836.
Immunosuppressive Drugs and COVID-19: A Review.
Schoot T, Kerckhoffs A, Hilbrands L, van Marum R
Front Pharmacol. 2020; 11:1333.
PMID: 32982743
PMC: 7485413.
DOI: 10.3389/fphar.2020.01333.
Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version).
Jin Y, Zhan Q, Peng Z, Ren X, Yin X, Cai L
Mil Med Res. 2020; 7(1):41.
PMID: 32887670
PMC: 7472403.
DOI: 10.1186/s40779-020-00270-8.
To immunosuppress: whom, when and how? That is the question with COVID-19.
Winthrop K, Mariette X
Ann Rheum Dis. 2020; 79(9):1129-1131.
PMID: 32753413
PMC: 7456547.
DOI: 10.1136/annrheumdis-2020-218694.